Gluconate De Calcium B.Braun

Calcium gluconate B.Braun is a calcium gluconate preparation supplied by B. Braun. It is a prescription‑only product marketed in the European Union. The formulation is intended for parenteral administration, available for intramuscular and intravenous injection. While the exact strength and dosage form are not specified in the label, the active ingredient provides calcium ions for physiological needs. It is classified as a calcium supplement and electrolyte replacement.

Calcium gluconate B.Braun is used to address conditions related to low calcium levels and to support specific electrolyte management in clinical practice.

- Treatment of hypocalcemia resulting from surgery, trauma, or endocrine disorders. - Management of calcium deficiency in patients receiving parenteral nutrition. - Adjunct therapy for hyperkalemia to protect cardiac membranes. - Counteracting magnesium toxicity by providing calcium ions. - Prevention of tetany in patients with impaired parathyroid function. - Support of bone mineralization during acute care when oral calcium is not feasible.

Adverse reactions to calcium gluconate B.Braun are generally infrequent, but they can be categorized by frequency and clinical significance.

Common: - Mild pain, redness, or swelling at the injection site. - Transient nausea or vomiting. - Temporary feeling of warmth or flushing. - Headache or dizziness shortly after administration.

Serious: - Severe hypercalcemia with symptoms such as confusion, muscle weakness, or cardiac arrhythmia. - Allergic reactions including rash, itching, bronchospasm, or anaphylaxis. - Extravasation causing tissue necrosis if the solution leaks into surrounding tissue. - Rapid drop in blood pressure (hypotension) especially with rapid IV infusion.

When administering calcium gluconate B.Braun, clinicians should observe several precautionary measures to minimize risk and ensure therapeutic effectiveness.

- Verify serum calcium levels before and after infusion to avoid over‑correction. - Use a controlled infusion rate; rapid IV administration can provoke cardiac disturbances. - Assess for a history of hypersensitivity to calcium salts or excipients. - Monitor cardiac rhythm continuously during intravenous delivery, especially in patients with underlying heart disease. - Avoid use in patients with severe hypercalcemia unless specifically indicated. - Ensure proper catheter placement to prevent extravasation and tissue injury. - Adjust dose in renal impairment, as calcium clearance may be reduced.

Calcium gluconate can interact with various medications; awareness of these interactions helps prevent adverse outcomes.

Avoid: - Concomitant use with bisphosphonates administered intravenously, which may cause acute hypocalcemia. - Simultaneous infusion with high‑dose loop diuretics that increase calcium excretion.

Use with caution: - Calcium channel blockers may enhance calcium’s effect on cardiac conduction; monitor ECG. - Digoxin therapy can be potentiated by calcium, increasing risk of toxicity. - Iron or zinc supplements may reduce calcium absorption; separate administration times. - Antacids containing aluminum or magnesium can alter calcium balance; observe serum levels.